Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):525-533. doi: 10.3760/cma.j.cn121090-20240608-00214.
Despite the continuous improvement in the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), acute graft-versus-host disease (GVHD) remains a major complication and cause of death. In recent years, with the emergence of new drugs for the prevention and treatment of acute GVHD and the update of a series of clinical studies, there have been varying degrees of changes in the routine prevention and treatment regimens for acute GVHD. Based on the main research achievements and the accumulation of clinical experience in this field in recent years, this consensus further updates the "The Consensus on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Diseases in China-Acute Graft-Versus-Host Disease (2020) .
尽管异基因造血干细胞移植（allo-HSCT）的疗效不断提高，但急性移植物抗宿主病（GVHD）仍然是主要并发症和死亡原因。近年来，随着急性GVHD防治新药的出现以及一系列临床研究的更新，急性GVHD的常规防治方案发生了不同程度的变化。基于该领域近年来的主要研究成果和临床经验积累，本共识进一步更新了《中国血液系统疾病异基因造血干细胞移植——急性移植物抗宿主病（2020年版）》。
